Stay updated on Long-term Safety of KarXT in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of KarXT in Schizophrenia Clinical Trial page.

Latest updates to the Long-term Safety of KarXT in Schizophrenia Clinical Trial page
- CheckyesterdayChange DetectedSponsor name updated to Karuna Therapeutics, Inc., a Bristol Myers Squibb company, replacing Karuna Therapeutics.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA new revision entry, v3.5.0, was added. The previous revision, v3.4.3, was removed from the Record History.SummaryDifference0.1%

- Check23 days agoChange DetectedA new revision entry v3.4.3 was added to the record history, and the previous revision v3.4.2 was removed from view.SummaryDifference0.1%

- Check51 days agoChange DetectedNew Revision: v3.4.2 added to the history and the temporary government-funding status notice (v3.4.1) was removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check58 days agoChange DetectedSite-wide funding notice was added and the record version updated to v3.4.1, replacing v3.4.0. These are minor metadata updates and do not affect study data, eligibility, or results.SummaryDifference0.8%

- Check65 days agoChange DetectedThe history page now shows a glossary toggle, green/red color-coded diffs, and updated version labels (No FEAR Act Data and Revision: v3.4.0), replacing the previous No FEAR Act data and Revision: v3.3.4. These are formatting and metadata changes and do not alter the core study information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

Stay in the know with updates to Long-term Safety of KarXT in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of KarXT in Schizophrenia Clinical Trial page.